Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed ...

Intellia Therapeutics, Inc.'s gene-editing therapies show strong potential with robust efficacy, safety, and market demand.

One of the companies mentioned in the letter is Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). Regeneron Pharmaceuticals Inc. ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of the top most undervalued biotech stocks to buy now. Guggenheim ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Shares of Regeneron Pharmaceuticals Inc. slipped 3.03% to $545.94 Monday, on what proved to be an all-around poor trading ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals is conducting a ...

CytomX's Phase I trial of ADC CX-2051 in colorectal cancer will continue based on a decision made by a safety committee ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

Cary Street Partners Financial LLC dramatically reduced its stake in Regeneron Pharmaceuticals. The firm now holds a mere 255 ...

Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025 -- ...